Table 1.
Characteristics of the included studies
| Study | Year | Country | Type | Disease | Participant number | Intervention details | Number of treatment | Age | Sex number | BCVA at baseline | CST at baseline | Follow up duration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bandello | 2018 | France, Germany, Israel, Italy, Spain, and the United Kingdom | RCT | BRVO | Total = 307 n(IVR) = 153 n(DEX) = 154 | IVR: 0.5 mg monthly given for 5 consecutive months than PRN DEX: 0.7 mg Ozurdox injection at month 1 and 5; PRN on month 10 or 11 |
IVR: 8.0 DEX: 2.5 | IVR: 65.5 ± 12.0 DEX: 68.4 ± 10.6 | IVR: M: 87; F: 67 DEX: M: 92; F: 61 | IVR: 59.2 ± 10.9 DEX: 56.6 ± 10.9 | IVR: 544 ± 168 DEX: 547 ± 163 | 12 |
| Feltgen | 2018 | German | RCT | BRVO | Total = 92 n(IVR) = 52 n(DEX) = 40 | IVR: 0.5 mg PRN injection DEX: 0.7 mg Ozurdox 1 dose given at the initial treatment or later; time interval of PRN is at least 5 months |
IVR: 4.46 ± 2.09 DEX: 0.40 ± 0.50 | IVR: 64.5 ± 9.7 DEX: 64.6 ± 9.9 | IVR: M: 18; F: 34 DEX: M: 22; F: 18 | IVR: 56.8 ± 10.0 DEX: 58.3 ± 10.8 | IVR: 563.3 ± 170.0 DEX: 547.3 ± 178.9 | 6 |
| Feltgen | 2018 | German | RCT | CRVO | Total = 83 n(IVR) = 61 n(DEX) = 22 | IVR: 0.5 mg PRN injection DEX: 0.7 mg Ozurdox 1 dose given at the initial treatment or later; time interval of PRN is at least 5 months |
IVR: 3.92 ± 2.64 DEX: 0.45 ± 0.51 | IVR: 66.6 ± 10.1 DEX: 61.1 ± 11.0 | IVR: M: 31; F: 30 DEX: M: 30; F: 8 | IVR: 54.1 ± 15.8 DEX: 53.2 ± 16.1 | IVR: 698.8 ± 228.6 DEX: 721.2 ± 231.1 | 6 |
| Hattenbach | 2018 | Germany, Great Britain, the Czech Republic, Poland and Hungary | RCT | BRVO | Total = 244 n(IVR) = 126 n(DEX) = 118 | IVR: 0.5 mg monthly given for 3 consecutive months than PRN DEX: 0.7 mg Ozurdox given at the initial treatment and monthly shame PRN injection | IVR: 4.71 DEX: 1 | N/A | N/A | N/A | N/A | 6 |
| Hoerauf | 2016 | Germany, Great Britain, Poland, and Hungary | RCT | CRVO | Total = 243 n(IVR) = 124 n(DEX) = 119 | IVR: 0.5 mg monthly given for 3 consecutive months than PRN DEX: 0.7 mg Ozurdox given at the initial treatment and monthly shame PRN injection | IVR: 4.52 DEX: 1 | IVR: 65.3 ± 11.4 DEX: 66.9 ± 12.4 | IVR: M: 72; F: 52 DEX: M: 73; F: 46 | IVR: 51.7 ± 16.5 DEX: 51.5 ± 15.6 | IVR: 723.8 ± 245.9 DEX: 705.2 ± 231.1 | 6 |